연속 혈당 모니터링 기기 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 연결 방식별, 적응증별, 유통 채널별, 지역별, 부문별 예측(2026-2033년)

Continuous Glucose Monitoring Devices Market Summary

The global continuous glucose monitoring devices market size was valued at USD 13.38 billion in 2025 and is projected to reach USD 49.87 billion by 2033, growing at a CAGR of 15.10% from 2026 to 2033. This growth is attributed to clinical needs, technological innovation, and shifting care models.

Another primary factor for market growth is the rising global prevalence of diabetes, which has intensified the demand for more efficient and real-time glucose monitoring solutions. Traditional blood glucose testing is often invasive, intermittent, and inconvenient, prompting both patients and providers to adopt continuous glucose monitoring (CGM) systems for better glycemic control and improved quality of life. According to the International Diabetes Federation (IDF), as of 2024, there are approximately 589 million adults living with diabetes worldwide.

CGM devices are minimally invasive and offer an easy and effective way to manage diabetes. They can also detect drastic changes in blood glucose levels, thereby preventing hypoglycemic conditions. The continuous glucose monitoring (CGM) devices facilitate the analysis of blood glucose levels at different time intervals with the help of a sensor. Respective readings fed into diabetes management software through a wireless network allow patients to understand the disease better, thereby helping them to manage it more effectively. Smoking, obesity, physical inactivity, high blood pressure, and high cholesterol are the common risk factors associated with diabetes complications. For instance, in January 2024, Medtronic received CE Mark approval in Europe for its MiniMed 780G system with Simplera Sync, a next-generation, minimally invasive CGM sensor that integrates fully with its automated insulin delivery pump.

The market is also witnessing a shift toward the increasing demand for personalized, real-time diabetes care. Unlike traditional fingerstick glucose monitoring, CGM devices offer continuous insights into glucose trends, helping patients and healthcare providers make proactive decisions. For instance, in August 2024, Abbott and Medtronic announced a global partnership to integrate Abbott's FreeStyle Libre CGM technology with Medtronic's automated insulin delivery systems. This was a critical step towards simplifying diabetes management and reducing the burden of constant self-monitoring. According to a key personnel member at Abbott Laboratories' Diabetes Care Division,

Global Continuous Glucose Monitoring Devices Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For the study, Grand View Research has segmented the continuous glucose monitoring devices market report based on product, connectivity, indication, distribution channel, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Sensors
• Device/Readers
• Applicators
• Transmitters
• Connectivity Outlook (Revenue, USD Million, 2021 - 2033)
• Bluetooth
• 4G/Cellular
• Near Field Communication (NFC)
• Indication Outlook (Revenue, USD Million, 2021 - 2033)
• Type 1 Diabetes
• Type 2 Diabetes
• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Pharmacies
• E-commerce
• Other
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Connectivity
  • 1.2.3. Indication
  • 1.2.4. Distribution Channel
  • 1.2.5. Regional scope
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Connectivity outlook
  • 2.2.3. Indication outlook
  • 2.2.4. Distribution channel outlook
  • 2.2.5. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Continuous Glucose Monitoring (CGM) Devices Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising number of diabetes cases
    • 3.2.1.2. Shift towards preventive and personalized care
    • 3.2.1.3. Technological advancements and device innovation
    • 3.2.1.4. Expansion of reimbursement and insurance coverage
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High cost of CGM devices
    • 3.2.2.2. Data accuracy and technical limitations
• 3.3. Continuous Glucose Monitoring (CGM) Devices Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape

Chapter 4. Continuous Glucose Monitoring (CGM) Devices Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Continuous Glucose Monitoring (CGM) Devices Market: Product Movement Analysis
• 4.3. Continuous Glucose Monitoring (CGM) Devices Market by Product Outlook (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 4.5. Sensors
  • 4.5.1. Sensors Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Device/Readers
  • 4.6.1. Device/Readers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.7. Applicators
  • 4.7.1. Applicators Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.8. Transmitters
  • 4.8.1. Transmitters Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Continuous Glucose Monitoring (CGM) Devices Market: Connectivity Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Continuous Glucose Monitoring (CGM) Devices Market: Connectivity Movement Analysis
• 5.3. Continuous Glucose Monitoring (CGM) Devices Market by Connectivity Outlook (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 5.5. Bluetooth
  • 5.5.1. Bluetooth Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. 4G/Cellular
  • 5.6.1. 4G/Cellular Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Near Field Communication (NFC)
  • 5.7.1. Near Field Communication Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Continuous Glucose Monitoring (CGM) Devices Market: Indication Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Continuous Glucose Monitoring (CGM) Devices Market: Indication Movement Analysis
• 6.3. Continuous Glucose Monitoring (CGM) Devices Market by Indication Outlook (USD Million)
• 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 6.5. Type 1 Diabetes
  • 6.5.1. Type 1 Diabetes Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Type 2 Diabetes
  • 6.6.1. Type 2 Diabetes Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Continuous Glucose Monitoring (CGM) Devices Market: Distribution Channel Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Continuous Glucose Monitoring (CGM) Devices Market: Distribution Channel Movement Analysis
• 7.3. Continuous Glucose Monitoring (CGM) Devices Market by Distribution Channel Outlook (USD Million)
• 7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 7.5. Pharmacies
  • 7.5.1. Pharmacies Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. E-commerce
  • 7.6.1. E-commerce Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. Others
  • 7.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Continuous Glucose Monitoring (CGM) Devices Market: Regional Estimates & Trend Analysis

• 8.1. Regional Dashboard
• 8.2. Regional Continuous Glucose Monitoring (CGM) Devices Market Movement Analysis
• 8.3. Continuous Glucose Monitoring (CGM) Devices Market: Regional Estimates & Trend Analysis by Product & End-use
• 8.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 8.5. North America
  • 8.5.1. North America Continuous Glucose Monitoring (CGM) Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.2. U.S.
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Reimbursement scenario
    • 8.5.2.5. U.S. Continuous Glucose Monitoring (CGM) Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.3. Canada
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Reimbursement scenario
    • 8.5.3.5. Canada Continuous Glucose Monitoring (CGM) Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.4. Mexico
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. Reimbursement scenario
    • 8.5.4.5. Mexico Continuous Glucose Monitoring (CGM) Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.6. Europe
  • 8.6.1. Europe Continuous Glucose Monitoring (CGM) Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.2. UK
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Reimbursement scenario
    • 8.6.2.5. UK Continuous Glucose Monitoring (CGM) Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.3. Germany
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Reimbursement scenario
    • 8.6.3.5. Germany Continuous Glucose Monitoring (CGM) Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.4. France
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Competitive Scenario
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. Reimbursement scenario
    • 8.6.4.5. France Continuous Glucose Monitoring (CGM) Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.5. Italy
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Competitive Scenario
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Reimbursement scenario
    • 8.6.5.5. Italy Continuous Glucose Monitoring (CGM) Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.6. Spain
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Competitive Scenario
    • 8.6.6.3. Regulatory Framework
    • 8.6.6.4. Reimbursement scenario
    • 8.6.6.5. Spain Continuous Glucose Monitoring (CGM) Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.7. Denmark
    • 8.6.7.1. Key Country Dynamics
  • 8.6.72. Competitive Scenario
    • 8.6.7.3. Regulatory Framework
    • 8.6.7.4. Reimbursement scenario
    • 8.6.7.5. Denmark Continuous Glucose Monitoring (CGM) Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.8. Sweden
    • 8.6.8.1. Key Country Dynamics
    • 8.6.8.2. Competitive Scenario
    • 8.6.8.3. Regulatory Framework
    • 8.6.8.4. Reimbursement scenario
    • 8.6.8.5. Sweden Continuous Glucose Monitoring (CGM) Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.9. Norway
    • 8.6.9.1. Key Country Dynamics
    • 8.6.9.2. Competitive Scenario
    • 8.6.9.3. Regulatory Framework
    • 8.6.9.4. Reimbursement scenario
    • 8.6.9.5. Norway Continuous Glucose Monitoring (CGM) Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.7. Asia Pacific
  • 8.7.1. Asia Pacific Continuous Glucose Monitoring (CGM) Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.2. Japan
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Competitive Scenario
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. Reimbursement scenario
    • 8.7.2.5. Japan Continuous Glucose Monitoring (CGM) Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.3. China
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Competitive Scenario
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. Reimbursement scenario
    • 8.7.3.5. China Continuous Glucose Monitoring (CGM) Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.4. India
    • 8.7.4.1. Key Country Dynamics
    • 8.7.4.2. Competitive Scenario
    • 8.7.4.3. Regulatory Framework
    • 8.7.4.4. Reimbursement scenario
    • 8.7.4.5. India Continuous Glucose Monitoring (CGM) Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.5. South Korea
    • 8.7.5.1. Key Country Dynamics
    • 8.7.5.2. Competitive Scenario
    • 8.7.5.3. Regulatory Framework
    • 8.7.5.4. Reimbursement scenario
    • 8.7.5.5. South Korea Continuous Glucose Monitoring (CGM) Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.6. Australia
    • 8.7.6.1. Key Country Dynamics
    • 8.7.6.2. Competitive Scenario
    • 8.7.6.3. Regulatory Framework
    • 8.7.6.4. Reimbursement scenario
    • 8.7.6.5. Australia Continuous Glucose Monitoring (CGM) Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.7. Thailand
    • 8.7.7.1. Key Country Dynamics
    • 8.7.7.2. Competitive Scenario
    • 8.7.7.3. Regulatory Framework
    • 8.7.7.4. Reimbursement scenario
    • 8.7.7.5. Thailand Continuous Glucose Monitoring (CGM) Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.8. Latin America
  • 8.8.1. Latin America Continuous Glucose Monitoring (CGM) Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.2. Brazil
    • 8.8.2.1. Key Country Dynamics
    • 8.8.2.2. Competitive Scenario
    • 8.8.2.3. Regulatory Framework
    • 8.8.2.4. Reimbursement scenario
    • 8.8.2.5. Brazil Continuous Glucose Monitoring (CGM) Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.3. Argentina
    • 8.8.3.1. Key Country Dynamics
    • 8.8.3.2. Competitive Scenario
    • 8.8.3.3. Regulatory Framework
    • 8.8.3.4. Reimbursement scenario
    • 8.8.3.5. Argentina Continuous Glucose Monitoring (CGM) Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.9. Middle East & Africa
  • 8.9.1. Middle East & Africa Continuous Glucose Monitoring (CGM) Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.9.2. South Africa
    • 8.9.2.1. Key Country Dynamics
    • 8.9.2.2. Competitive Scenario
    • 8.9.2.3. Regulatory Framework
    • 8.9.2.4. Reimbursement scenario
    • 8.9.2.5. South Africa Continuous Glucose Monitoring (CGM) Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.9.3. Saudi Arabia
    • 8.9.3.1. Key Country Dynamics
    • 8.9.3.2. Competitive Scenario
    • 8.9.3.3. Regulatory Framework
    • 8.9.3.4. Reimbursement scenario
    • 8.9.3.5. Saudi Arabia Continuous Glucose Monitoring (CGM) Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.9.4. UAE
    • 8.9.4.1. Key Country Dynamics
    • 8.9.4.2. Competitive Scenario
    • 8.9.4.3. Regulatory Framework
    • 8.9.4.4. Reimbursement scenario
    • 8.9.4.5. UAE Continuous Glucose Monitoring (CGM) Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.9.5. Kuwait
    • 8.9.5.1. Key Country Dynamics
    • 8.9.5.2. Competitive Scenario
    • 8.9.5.3. Regulatory Framework
    • 8.9.5.4. Reimbursement scenario
    • 8.9.5.5. Kuwait Continuous Glucose Monitoring (CGM) Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Market Participant Categorization
• 9.2. Key Company Profiles
  • 9.2.1. DexCom, Inc.
    • 9.2.1.1. Company overview
    • 9.2.1.2. Financial performance
    • 9.2.1.3. Product benchmarking
    • 9.2.1.4. Strategic initiatives
  • 9.2.2. Abbott Laboratories
    • 9.2.2.1. Company overview
    • 9.2.2.2. Financial performance
    • 9.2.2.3. Product benchmarking
    • 9.2.2.4. Strategic initiatives
  • 9.2.3. Medtronic plc
    • 9.2.3.1. Company overview
    • 9.2.3.2. Financial performance
    • 9.2.3.3. Product benchmarking
    • 9.2.3.4. Strategic initiatives
  • 9.2.4. Sensonics Holdings, Inc.
    • 9.2.4.1. Company overview
    • 9.2.4.2. Financial performance
    • 9.2.4.3. Product benchmarking
    • 9.2.4.4. Strategic initiatives
  • 9.2.5. Sinocare, Inc
    • 9.2.5.1. Company overview
    • 9.2.5.2. Financial performance
    • 9.2.5.3. Product benchmarking
    • 9.2.5.4. Strategic initiatives
  • 9.2.6. i-SENS, Inc.
    • 9.2.6.1. Company overview
    • 9.2.6.2. Financial performance
    • 9.2.6.3. Product benchmarking
    • 9.2.6.4. Strategic initiatives
  • 9.2.7. Zhejiang POCTech Co., Ltd.
    • 9.2.7.1. Company overview
    • 9.2.7.2. Financial performance
    • 9.2.7.3. Product benchmarking
    • 9.2.7.4. Strategic initiatives
  • 9.2.8. GlucoRx Limited
    • 9.2.8.1. Company overview
    • 9.2.8.2. Financial performance
    • 9.2.8.3. Product benchmarking
    • 9.2.8.4. Strategic initiatives
  • 9.2.9. F. Hoffmann-La Roche Ltd.
    • 9.2.9.1. Company overview
    • 9.2.9.2. Financial performance
    • 9.2.9.3. Product benchmarking
    • 9.2.9.4. Strategic initiatives
  • 9.2.10. Nemaura
    • 9.2.10.1. Company overview
    • 9.2.10.2. Financial performance
    • 9.2.10.3. Product benchmarking
    • 9.2.10.4. Strategic initiatives
  • 9.2.11. Bionime
    • 9.2.11.1. Company overview
    • 9.2.11.2. Financial performance
    • 9.2.11.3. Product benchmarking
    • 9.2.11.4. Strategic initiatives